BB Biotech AG (0JYO)

London


	Symbol		Exchange		Currency
	BIONn		Xetra		EUR	Delayed
	BBZAd		BATS Europe		EUR	Delayed
	BIONz		BATS Europe		CHF	Delayed
	0JYO		London		CHF	Real-time
	BION		Switzerland		CHF	Delayed
	BIONn		Frankfurt		EUR	Delayed

Currency in CHF

36.78

-0.11(-0.30%)

Closed15/10

Fair Value

Day's Range

36.30

37.00

52 wk Range

35.45

49.75

0JYO Income Statement

Featured here, the Income Statement (earnings report) for BB Biotech AG, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

727.79

741.76

-

0

0.04

Total Revenues Growth

+13,163.86%

+1.92%

-

-

+775%

Cost Of Revenues

-

-

-

-

-

Gross Profit

727.79

741.76

-

0

0.04

Gross Profit Growth

+13,163.86%

+1.92%

-

-

+775%

Gross Profit Margin %

100%

100%

-

100%

100%

Other Operating Expenses, Total

47.87

47.77

59.2

43.02

34.64

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+3.98%	-0.21%	+23.92%	-27.33%	-19.48%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	42.38	41.76	52.6	38.63	29.96
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	5.5	6.02	6.6	4.39	4.68

Operating Income

679.92

693.99

-59.2

-43.01

-34.6

Operating Income Growth

+1,776.65%

+2.07%

-108.53%

+27.34%

+19.55%

EBIT Margin %

93.42%

93.56%

-

-1,075,325%

-98,865.71%

Net Interest Expenses

-1.24

-0.88

-0.99

-1.73

-5.8

Net Interest Expenses Growth

-14.46%

+28.96%

-11.66%

-75.05%

-236.15%

Interest Expense, Total

-1.24

-0.88

-0.99

-1.73

-5.8

Interest And Investment Income

-

-

-

-

-

Other Non Operating Expenses, Total

-1.17

-1.86

-0.96

1.25

0.49

EBT, Excl. Unusual Items

677.5

691.25

-61.15

-43.49

-39.92

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-

-

-

-

-

EBT, Incl. Unusual Items

677.5

691.25

-404.74

-357.75

-206.53

EBT, Incl. Unusual Items Growth

+243.76%

+2.03%

-158.55%

+11.61%

+42.27%

EBT, Incl. Unusual Items Margin

93.09%

93.19%

-

-8,943,775%

-590,080%

Income Tax Expense

0.07

0.08

0.07

0.06

0.08

Net Income to Company

677.43

691.17

-404.81

-357.81

-206.61

Minority Interest

-

-

-

-

-

Net Income

677.43

691.17

-404.81

-357.81

-206.61

Net Income Growth

+243.72%

+2.03%

-158.57%

+11.61%

+42.26%

Net Income Margin %

93.08%

93.18%

-

-8,945,300%

-590,305.71%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

677.43

691.17

-404.81

-357.81

-206.61

Basic EPS - Continuing Operations

12.23

12.48

-7.31

-6.5

-3.77

Basic EPS - Continuing Operations Growth

+243.72%

+2.04%

-158.6%

+11.04%

+42.08%

Diluted EPS - Continuing Operations

12.23

12.48

-7.31

-6.5

-3.77

Diluted EPS - Continuing Operations Growth

+243.69%

+2.04%

-158.6%

+11.04%

+42.04%

Basic Weighted Average Shares Outstanding

55.4

55.39

55.36

55.01

54.85

Diluted Weighted Average Shares Outstanding

55.4

55.39

55.36

55.01

54.85

Dividend Per Share

3.4

3.6

3.85

2.85

2

Dividend Per Share Growth

+11.48%

+5.88%

+6.94%

-25.97%

-29.82%

EBITDA

-

-

-

-

-

EBITDA Growth

-

-

-

-

-

EBITDA Margin %

-

-

-

-

-

EBIT